Pembrolizumab shows clinical promise as a treatment for mycosis fungoides and Sézary syndrome, achieving a response in nearly ...

Yelena Y. Janjigian, MD, discusses the long-term survival data from the KEYNOTE-811 trial of pembrolizumab plus trastuzumab ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

MSD’s monoclonal antibody, indicated for 15 types of cancer, smashed industry records with sales of $27.3 billion in 2024, ...

Real world data show that immunotherapy leads to better overall survival outcomes than chemotherapy in patients with ...

First NK Cell Therapy Approval Expected By 2028 Says Kuick Research In Its New Research Study On Global NK Cell Therapy ...

NIH trial shows new form of TIL therapy effective against colon, rectum, pancreas, and bile duct tumors.

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell ...

Hello and welcome to the AIM ImmunoTech fourth-quarter and full-year 2024 update conference call and webcast. (Operator Instructions) Note that this webcast is being recorded at the company's request, ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

CG Oncology (NASDAQ:CGON – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright ...